Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bleomycin].

H Niitani1

  • 1Dept. of Clinical Pathology, Nippon Medical School.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 1, 1987
PubMed
Summary
This summary is machine-generated.

Bleomycin is a chemotherapy drug effective against various tumors. Careful administration is crucial to mitigate pulmonary toxicity, its primary dose-limiting side effect.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cross-resistance to antineoplastic agents in a human small-cell lung-cancer subline resistant to okadaic Acid.

Oncology reports·2011
Same author

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.

British journal of cancer·2003
Same author

The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): validity and reliability in japanese patients with advanced non-small-cell lung cancer.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2002
Same author

A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in non-small-cell lung cancer: 3-week schedule.

International journal of clinical oncology·2002
Same author

Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer.

International journal of clinical oncology·2001
Same author

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.

British journal of cancer·2001
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Context:

  • Bleomycin, discovered by H. Umezawa et al., is a globally utilized chemotherapy agent.
  • Its efficacy is established against tumors like squamous epithelial carcinoma and malignant lymphoma.

Purpose:

  • To elucidate the molecular mechanism of Bleomycin's antitumor activity.
  • To review Bleomycin's clinical applications, derivative development, and side effect management.

Summary:

  • Bleomycin functions by cutting DNA chains via a ferrum chelate (BLM-Fe(III) chelate).
  • Novel dosage forms and derivatives, such as Peplomycin, have been developed to enhance efficacy and reduce toxicity.
  • Clinical use involves combination therapy with other agents, surgery, and radiation.

Impact:

  • Bleomycin exhibits no myelotoxicity but poses a risk of pulmonary toxicity, necessitating careful patient selection and administration.
  • Understanding and managing Bleomycin-induced pulmonary toxicity is critical for optimizing patient outcomes in cancer treatment.